Figure 7.

Braco-19 and TMPyP4 inhibit viral protein synthesis and genome replication

(A–D) Vero cells were either mock-infected (M) or infected with ZIKV at an MOI of 1 and subsequently incubated in medium containing 0, 1 μM, 10 μM, and 100 μM concentrations of Braco-19 (A and B) or TMPyP4 (C and D). Cell extracts were prepared at 48 hpi (A and C) or 96 hpi (B and D) and 20 μg of proteins from each sample were analyzed by SDS-PAGE and western blotting with 4G2 antibody to detect viral E protein. Levels of actin detected in the blots using anti-actin antibody served as the loading control. Molecular mass markers (in kDa) are shown on the left. Representative data are shown in each panel. (E) Levels of viral genome in the presence of Braco-19 or TMPyP4. Vero cells infected as above were and incubated in medium without drug (untreated) or containing 100 μM Braco-19 or 10 μM TMPyP4. Viral genome copies in the cells at 72 and 96 hpi were quantitated and expressed as copies per μg of total cellular RNA from the cells. The graphs show mean values of genome copy numbers with error bars representing standard deviations from the results of three independent experiments. Two-way ANOVA was used to determine significant differences between untreated and drug-treated samples. ∗∗∗∗p ≤ 0.0001; ∗∗∗p ≤ 0.001.